Clinical Trials

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07418749 2026-02-18

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07415031 2026-02-17

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Other solid neoplasmThoracic

126 enrolled

Mesothelioma, Malignant

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

500 enrolled

Phase 2/3 Not yet recruiting

Non Squamous Non-small Cell Lung Cancer

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

60 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07154368 2025-09-19

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

207 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07157956 2025-09-05

CVL006-T1002

318 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

278 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

76 enrolled

NSCLC

NCT06890182 2025-03-21

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

31 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

430 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06688656 2024-11-14

Peri-E

30 enrolled

Phase NA Not yet recruiting

Lung Neoplasms

NCT06649448 2024-10-18

EF-001

200 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT06497543 2024-09-19

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

80 enrolled

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

350 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

178 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

30 enrolled

Non-small Cell Lung Cancer Metastatic

NCT05805631 2024-05-01

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

23 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06391008 2024-04-30

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

44 enrolled

Phase 2/3 Not yet recruiting

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

401 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

642 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05132985 2021-12-10

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04153734 2019-11-06

Evolution

21 enrolled